Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score
Risk of disease reactivation after discontinuation from DMF/TERI can be stratified with the VIAADISC score and appears to be safe above age 45-55 and with long-lasting stability. However, risk after de-escalation from NTZ/FTY is too high to allow reliable stratification and should be avoided by lateral switch.
Authors
- Christiane Gradl
- Franziska Di Pauli (ORCID: https://orcid.org/0000-0001-6183-2394)
- Robert Barket (ORCID: https://orcid.org/0000-0001-6909-6109)
- Harald Hegen
- Gerhard Traxler
- Gabriel Bsteh (ORCID: https://orcid.org/0000-0002-0825-0851)
- Markus Ponleitner (ORCID: https://orcid.org/0000-0002-3709-1845)
- Robert Hoepner (ORCID: https://orcid.org/0000-0002-0115-7021)
- Florian Deisenhammer (ORCID: https://orcid.org/0000-0003-4541-8841)
- Nik Krajnc (ORCID: https://orcid.org/0000-0002-4146-5870)
- Andrew Chan
- Helly Hammer (ORCID: https://orcid.org/0000-0003-3486-3448)
- Tobias Zrzavy (ORCID: https://orcid.org/0000-0001-8909-1591)
- Thomas Berger (ORCID: https://orcid.org/0000-0002-2432-7791)
- Fabian Föttinger (ORCID: https://orcid.org/0009-0005-7970-5349)
- Vincenzo P Introcaso
Institutions
- University of Bern (CH)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- University of Applied Sciences St Pölten (AT)
- University Hospital of Bern (CH)
- Comprehensive Cancer Center Vienna (AT)
- Universitätsklinikum St. Pölten (AT)
- Kepler Universitätsklinikum (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1016/j.msard.2025.106691
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- CSL Behring
- European Committee for Treatment and Research in Multiple Sclerosis
- University of Bern
- Merck KGaA
- Amicus Therapeutics
- European Commission
- Neuraxpharm
- MedDay Pharmaceuticals
- Allergan